Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The newly approved indication authorizes the drug's use in combination with immunosuppressive therapy for patients aged 15 years and above with newly-diagnosed severe aplastic anemia (SAA). Hetrombopag Olamine Tablets were originally approved for marketing in 2021 with two indications: first, for adult patients with chronic primary immune thrombocytopenia (ITP) who had insufficient response to previous treatments such as corticosteroids or immunoglobulins; and second, for adult patients with severe aplastic anemia (SAA) who showed poor efficacy following immunosuppressive therapy (IST).